Abstract | BACKGROUND: AIM: METHODS: Thirty neuroleptic-treated patients with schizophrenia were randomly allocated in a double-blind design to receive either mianserin (15 mg/day) or placebo for five days. Patients were assessed at baseline and on Days 3 and 5 by the Barnes Akathisia Scale (BARS), as well as by other relevant clinical rating scales. RESULTS: Compared with the placebo group, the mianserin-treated patients showed a significant reduction in all four BARS subscales by Day 5, with mean reductions in the BARS global score of 9.9% and 52.2%, respectively (P = 0.006). Response to treatment (a reduction of at least two points on the BARS global subscale), was noted in six patients (40%) in the mianserin group and only one patient (9.1%) in the placebo group (P = 0.04, log odds ratio 2.23). CONCLUSIONS:
|
Authors | M Poyurovsky, M Shardorodsky, C Fuchs, M Schneidman, A Weizman |
Journal | The British journal of psychiatry : the journal of mental science
(Br J Psychiatry)
Vol. 174
Pg. 238-42
(Mar 1999)
ISSN: 0007-1250 [Print] England |
PMID | 10448449
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Serotonin Antagonists
- Mianserin
|
Topics |
- Adult
- Akathisia, Drug-Induced
(drug therapy, etiology)
- Double-Blind Method
- Female
- Humans
- Male
- Mianserin
(therapeutic use)
- Schizophrenia
(drug therapy)
- Serotonin Antagonists
(therapeutic use)
- Treatment Outcome
|